• Earlier in May 2026, Arrowhead Pharmaceuticals reported a sharp drop in quarterly sales to US$73.74 million and moved from net income to a net loss of US$132.73 million, while also filing a roughly US$1.00 billion shelf registration tied to an ESOP-related common stock offering.
• At the same time, Arrowhead announced an exclusive worldwide license of its ARO-PNPLA3 MASH program to Madrigal Pharmaceuticals, with US$25 million upfront and up to US$975 million in potential milestones plus tiered royalties, underlining how partnered RNAi assets may help offset earnings pressure from weaker product and collaboration revenue.
• We’ll examine how the ARO-PNPLA3 licensing deal with Madrigal could reshape Arrowhead’s investment narrative amid its evolving commercial profile.

Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.

Arrowhead Pharmaceuticals Investment Narrative Recap

To own Arrowhead today, you have to believe its RNAi platform and new commercial footing with REDEMPLO can eventually outweigh lumpier collaboration revenue and rising losses. The sharp Q2 swing to a US$132.73 million net loss, combined with a US$1.00 billion shelf registration, keeps funding and dilution risk front and center, while near term, execution on REDEMPLO launches and late stage plozasiran data still looks like the key catalyst.

The ARO PNPLA3 licensing deal with Madrigal Pharmaceuticals sits right in the middle of that tension. The US$25 million upfront and up to US$975 million in milestones and royalties highlight how Arrowhead can recycle clinical assets into potential future cash streams, helping to offset weaker product and collaboration revenue as the company leans more on partnered programs to support its commercial transition.

Yet, despite the excitement around partnering and first product launches, investors should also be aware of how quickly rising cash burn could...

Arrowhead Pharmaceuticals’ narrative projects $398.8 million revenue and $64.0 million earnings by 2028.

Uncover how Arrowhead Pharmaceuticals' forecasts yield a $64.08 fair value, a 16% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already penciling in about US$1.1 billion of revenue and roughly US$180 million of earnings by 2029, which sits in sharp contrast to the current concern about growing losses and future dilution risk. This new setback may push those upbeat assumptions to be revisited, so it is worth comparing how your own expectations line up with both the bullish and more cautious views before deciding what feels reasonable.

Explore 3 other fair value estimates on Arrowhead Pharmaceuticals - why the stock might be worth 16% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Arrowhead Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Arrowhead Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arrowhead Pharmaceuticals' overall financial health at a glance.

Ready For A Different Approach?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• Uncover the next big thing with 27 elite penny stocks that balance risk and reward.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.